{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:13:17Z","timestamp":1775535197519,"version":"3.50.1"},"reference-count":74,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Trastuzumab deruxtecan (T\u2010DXd) is a third\u2010generation, HER2\u2010targeting antibody\u2010drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have \u201cHER2\u2010low\u201d (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization\u2010negative) unresectable or metastatic breast cancer and who have received prior chemotherapy in the metastatic setting or developed disease recurrence during, or within 6 months of completing, adjuvant chemotherapy. The broad aims of this paper are: (a) To draw attention to some of the challenges associated with identifying whether patients have HER2\u2010low metastatic breast cancer (mBC), in an environment where healthcare professionals have previously only needed to determine whether mBC is HER2\u2010positive and therefore likely to respond to traditional HER2\u2010targeted therapies; and (b) to indicate, where possible, what might be done to help overcome specific challenges in this regard. Advice regarding the management of specific T\u2010DXd\u2010related side effects of interest, including interstitial lung disease and pneumonitis, left ventricular dysfunction and emesis, is also offered.<\/jats:p>","DOI":"10.1111\/ajco.70069","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:22:13Z","timestamp":1769847733000},"page":"381-391","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab Deruxtecan for HER2\u2010Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia"],"prefix":"10.1111","volume":"22","author":[{"given":"Andrew","family":"Redfern","sequence":"first","affiliation":[{"name":"Fiona Stanley Hospital  Murdoch Western Australia Australia"},{"name":"University of Western Australia  Crawley Western Australia Australia"},{"name":"Harry Perkins Institute of Medical Research  Nedlands Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Lakhani","sequence":"additional","affiliation":[{"name":"University of Queensland Centre For Clinical Research  Brisbane Queensland Australia"},{"name":"Pathology Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmala","family":"Pathmanathan","sequence":"additional","affiliation":[{"name":"Westmead Breast Cancer Institute Westmead Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"},{"name":"Douglass Hanly Moir Pathology, Macquarie Park  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarsha","family":"Selva\u2010Nayagam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"McCarthy","sequence":"additional","affiliation":[{"name":"ICON Cancer Centre Wesley, Auchenflower  Brisbane Queensland Australia"},{"name":"University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Yeo","sequence":"additional","affiliation":[{"name":"Austin Health  Melbourne Victoria Australia"},{"name":"Olivia Newton\u2010John Cancer Research Institute  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Dessauvagie","sequence":"additional","affiliation":[{"name":"Clinipath Pathology, Osborne Park  Perth Western Australia Australia"},{"name":"UWA Medical School University of Western Australia, Crawley  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelareh","family":"Farshid","sequence":"additional","affiliation":[{"name":"Discipline of Medicine, University of Adelaide  Adelaide South Australia Australia"},{"name":"Directorate of Anatomical Pathology, SA Pathology, Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/00313020120083133"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.02.004"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0703"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102989"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010126"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S366122"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.008"},{"key":"e_1_2_8_14_1","unstructured":"\"Manual of Use and Interpretation of Pathology Tests \"Royal College of Pathologists of Australasia accessed September 2024 https:\/\/www.rcpa.edu.au\/Manuals\/RCPA\u2010Manual."},{"key":"e_1_2_8_15_1","unstructured":"\"Structured Reporting Protocol for Invasive Carcinoma of the Breast (3rd Edition 2022) \"Royal College of Pathologists of Australsia accessed September 2024 https:\/\/www.rcpa.edu.au\/Library\/Practising\u2010Pathology\/Structured\u2010Pathology\u2010Reporting\u2010of\u2010Cancer\/Cancer\u2010Protocols\/Breast\/Protocol\u2010Invasive\u2010breast.aspx."},{"key":"e_1_2_8_16_1","unstructured":"\"Guideline: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines\u2014Recommendations for Practice in Australasia \"Royal College of Pathologists of Australasia accessed September 2024 https:\/\/www.rcpa.edu.au\/getattachment\/fecd094c\u2010aaf4\u2010416b\u20109ed5\u20104a61f5ac1a93\/ASCO\u2010CAP\u20102018\u2010HER2\u2010Testing\u2010for\u2010Breast\u2010Cancer\u2010Guide.aspx."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_2_8_18_1","unstructured":"\"ENHERTU\u00ae (Trastuzumab Deruxtecan) Powder for Injection \"Australian Product Information published May 2024 https:\/\/www.tga.gov.au\/sites\/default\/files\/2024\u201009\/auspar\u2010enhertu\u2010240906\u2010pi.pdf."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_2_8_21_1","unstructured":"AstraZeneca \"Press Release: Enhertu Approved in the EU as the First HER2\u2010Directed Therapy for Patients With HER2\u2010Low Metastatic Breast Cancer \" published 26 January 2023 https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2023\/enhertu\u2010approved\u2010in\u2010the\u2010eu\u2010as\u2010the\u2010first\u2010her2\u2010directed\u2010therapy\u2010for\u2010patients\u2010with\u2010her2\u2010low\u2010metastatic\u2010breast\u2010cancer.html."},{"key":"e_1_2_8_22_1","unstructured":"US Food and Drug Administration \"FDA Approves Fam\u2010Trastuzumab Deruxtecan\u2010Nxki for HER2\u2010Low Breast Cancer \" published 5 August 2022 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010fam\u2010trastuzumab\u2010deruxtecan\u2010nxki\u2010her2\u2010low\u2010breast\u2010cancer."},{"key":"e_1_2_8_23_1","unstructured":"AstraZeneca \"Press Release: Enhertu Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression\u2010Free Survival in HR\u2010Positive HER2\u2010Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY\u2010Breast06 Phase III Trial \" published 29 April 2024 https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2024\/enhertu\u2010improved\u2010pfs\u2010in\u2010her2\u2010low\u2010and\u2010ultralow.html."},{"key":"e_1_2_8_24_1","unstructured":"\"Prescription Medicines Registrations \"Commonwealth Department of Health and Aged Care accessed September 2024 https:\/\/www.tga.gov.au\/resources\/prescription\u2010medicines\u2010registrations?keywords=enhertu."},{"key":"e_1_2_8_25_1","unstructured":"Daiichi Sankyo \"Press Release: ENHERTU\u00aeApproved in Japan as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer \" published 27 March 2023 https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202303\/20230327_E.pdf."},{"key":"e_1_2_8_26_1","unstructured":"\u201cNew Drug Indication Approval\u2010April 2023 \u201d Singapore Health Sciences Authority accessed September 2024 https:\/\/www.hsa.gov.sg\/announcements\/new\u2010drug\u2010indication\u2010approvals\/new\u2010drug\u2010indication\u2010approval\u2010april\u20102023."},{"key":"e_1_2_8_27_1","unstructured":"\"Trastuzumab Deruxtecan \"Department of Health and Aged Care accessed September 2024 https:\/\/www.pbs.gov.au\/medicine\/item\/13713R\u201013718B\u201014577F\u201014578G."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090582"},{"key":"e_1_2_8_32_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology Antiemesis","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"e_1_2_8_33_1","unstructured":"\"Prevention of Anti\u2010Cancer Therapy Induced Nausea and Vomiting \"Cancer Institute NSW eviQ Guidelines accessed September 2024 https:\/\/www.eviq.org.au\/clinical\u2010resources\/side\u2010effect\u2010and\u2010toxicity\u2010management\/gastrointestinal\/7\u2010prevention\u2010of\u2010anti\u2010cancer\u2010therapy\u2010induced\u2010nausea."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058\u2010025\u201001967\u20101)"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00097"},{"key":"e_1_2_8_36_1","unstructured":"\"Herceptin (Trastuzumab) \"Australian Product Information published May 2021."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101615"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523\u2010020\u201000208\u20102)"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0617-OA"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1176309"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.29"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e328359cf9a"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.19.1173"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.08.007"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001321"},{"issue":"5","key":"e_1_2_8_46_1","first-page":"HER2","article-title":"Abstract HER2\u201018: HER2\u201018 Determination of HER2\u2010Low Status in Tumors of Patients With Unresectable and\/or Metastatic Breast Cancer in DESTINY\u2010Breast04","volume":"83","author":"Prat A.","journal-title":"Cancer Research"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523\u2010021\u201000343\u20104)"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.022"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02287-x"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051413"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100087"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14010031"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021064"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12154882"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.04.026"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.36"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP09VUTZWZXBMJ"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103883"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102286"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100032"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7239"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100535"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","unstructured":"J.R\u00fcschoff A.Penner I.Ellis et\u00a0al. \"Proficiency Assessment of HER2\u2010low Breast Cancer Scoring with the Ventana PATHWAY 4B5 and Dako HercepTest HER2 Assays and the Impact of Pathologist Training \"poster presented at San Antonio Breast Cancer Symposium Annual Meeting (San Antonio USA) December 6\u201310 2022.","DOI":"10.1158\/1538-7445.SABCS22-HER2-13"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000\u2010025\u201001624\u20103"},{"key":"e_1_2_8_65_1","doi-asserted-by":"crossref","unstructured":"G.Curigliano X.Hu R. A.Dent et\u00a0al.Trastuzumab deruxtecan (T\u2010DXd) vs physician's Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor\u2010Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)\u2010Low or HER2\u2010Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary results from DESTINY\u2010Breast06 (DB\u201006). Presented at ASCO 31 May\u20134 June 2024 Chicago USA; abstract LBA1000.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14800-w"},{"key":"e_1_2_8_67_1","first-page":"1177","article-title":"Prognostic and Biologic Significance of ERBB2\u2010Low Expression in Early\u2010Stage Breast Cancer","volume":"8","author":"Tarantino P.","year":"2022","journal-title":"JAMA Oncology"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2"},{"key":"e_1_2_8_69_1","unstructured":"Study of Trastuzumab Deruxtecan (T\u2010Dxd) vs Investigator's Choice Chemotherapy in HER2 low Hormone Receptor Positive. Metastatic Breast Cancer (DB\u201006). ClinicalTrials.gov Identifier: NCT04494425 accessed January 2026 https:\/\/clinicaltrials.gov\/study\/NCT04494425."},{"key":"e_1_2_8_70_1","unstructured":"Trastuzumab Deruxtecan (T\u2010Dxd) in patients who have hormone receptor\u2010negative and hormone receptor\u2010positive HER2\u2010low or HER2 IHC 0 metastatic breast cancer. ClinicalTrials.gov Identifier: NCT05950945 accessed January 2026 https:\/\/clinicaltrials.gov\/study\/NCT05950945."},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-022-00804-9"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvab047"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100054"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.516"},{"issue":"4","key":"e_1_2_8_75_1","article-title":"Novel Approach to HER2 Quantification: Digital Pathology Coupled With AI\u2010Based Image and Data Analysis Delivers Objective and Quantitative HER2 Expression Analysis for Enrichment of Responders to Trastuzumab Deruxtecan (T\u2010DXd; DS\u20108201), Specifically in HER2\u2010Low Patients","volume":"81","author":"Gustavson M.","year":"2021","journal-title":"Cancer Research"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:34:19Z","timestamp":1775532859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ajco.70069"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70069","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}